LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarker Identifies Septic Patients at Higher Risk for Mortality

By LabMedica International staff writers
Posted on 28 Jan 2020
Print article
Image: Blood smear of patient with intracellular cocci in pairs inside a white blood cell, possibly indicating sepsis. Oncostatin-M is a biomarker for sepsis risk (Photo courtesy of Dr. Wim van der Meer).
Image: Blood smear of patient with intracellular cocci in pairs inside a white blood cell, possibly indicating sepsis. Oncostatin-M is a biomarker for sepsis risk (Photo courtesy of Dr. Wim van der Meer).
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion.

Oncostatin-M (OSM) is a pleiotropic cytokine of the interleukin-6 (IL-6) family. OSM secretion has been associated with the modulation of multiple inflammatory diseases, including rheumatoid arthritis, asthma, inflammatory bowel disease, osteoarthritis, hepatic cellular carcinoma and bacterial pneumonia. However, the role of OSM in sepsis has remained unclear.
Laboratory scientists at the Chongqing Medical University (Chongqing, China) enrolled 49 patients with sepsis at the Second Affiliated Hospital of the university intensive care unit (ICU) between October 2017 and December 2018 and analyzed serum OSM levels on their day of admission. The effects of OSM on polymicrobial sepsis induced by cecal ligation and puncture (CLP) were assessed.

The team reported that results of the study showed that on day 1 of ICU admission, septic patients had higher serum OSM levels compared with ICU patient controls and healthy volunteers. Further, they found that a high serum OSM level at ICU admission was independently predictive of 28-day mortality in septic patients, as was SOFA score. They reported that the area under the curve (AUC) of OSM for predicting 28-day mortality in septic patients was 0.80 on day of ICU admission which was significantly higher than that of SOFA score (AUC, 0.730) and procalcitonin (AUC, 0.65). The findings were supported in a mouse model. In CLP-induced polymicrobial sepsis, anti-OSM antibody decreased tissue inflammation and injury, and thus improved survival, while local and systemic bacterial dissemination was almost constant.

The authors concluded that their pilot study found a significant elevation in the serum OSM levels in the patients with sepsis, and OSM levels correlated with disease severity of sepsis. Moreover, the serum OSM level on day of ICU admission was related to 28-day mortality in septic patients. These results suggest that OSM measurement may represent a new biomarker for identification of a group of septic patients presenting with higher risk of mortality. The study was published on January 13, 2020 in the Journal of Infectious Diseases.

Related Links:
Chongqing Medical University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.